Pharma Equity Group (PEG) Investor Update summary

Regulatory milestone achieved

• Received approval to initiate a pivotal Phase 2 clinical trial for RNX-011 targeting secondary peritonitis, a life-threatening intra-abdominal infection with high mortality.

• Approval validates the scientific strategy and marks a key commercial milestone, strengthening the position for future partner negotiations.

Study design and objectives

• The trial is randomized, placebo-controlled, and will test a triple-action therapy (fosfomycin, metronidazole, GM-CSF) administered during surgery.

• Primary endpoint is reduction in serious postoperative complications, with secondary measures including local inflammation (IL-6) and overall recovery (QoR-15).

• Enrollment of 32 patients is planned, with the first patient expected in Q4 2025.

Strategic focus and future outlook

• All resources are currently dedicated to advancing Reponex Pharmaceuticals' projects, with a focus on innovative therapies and improving healthcare outcomes.

• Long-term strategy includes exploring new investments only after realizing the full potential of current medical projects.